Outlook Therapeutics Inc OTLK

NAS: OTLK | ISIN: US69012T2069   20:15
7,990 USD (+2,70%)
(+2,70%)   20:15
Grafiek Outlook Therapeutics Inc Grafiek Outlook Therapeutics Inc

Outlook Therapeutics Inc in het nieuws

28 december 2023 · OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

28 december 2023 · OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options · Persbericht

21 december 2023 · OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options · Persbericht

14 december 2023 · OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

5 december 2023 · OUTLOOK SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options · Persbericht

13 november 2023 · Outlook Investor Deadline Approaching · Persbericht

13 november 2023 · SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Outlook Investors of a Lead Plaintiff Deadline of January 2, 2024 · Persbericht

11 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLK · Persbericht

11 november 2023 · ROSEN, AN INVESTOR RIGHTS LAW FIRM, Encourages Outlook Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - OTLK · Persbericht

9 november 2023 · Outlook Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Outlook Therapeutics, Inc. · Persbericht

Profiel Outlook Therapeutics Inc

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: outlooktherapeutics.com

Hoofdzetel: Monmouth Junction, New Jersey vlag Verenigde Staten

CEO: Lawrence Kenyon

Werknemers: 18

Aandelen Outlook Therapeutics Inc

Beurswaarde: 182,10 miljoen USD

Effecten: 23,41 miljoen

Winst per aandeel (12 maand):  PLUS

Beta: 0,42

Mijn selecties